{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:12:29Z","timestamp":1793319149418,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07888-7","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:47:40Z","timestamp":1772527660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exercise-mobilized lymphocytes enhance antibody-based immunotherapy in multiple myeloma through CD16+ NK cell\u2013mediated cytotoxicity"],"prefix":"10.1186","volume":"24","author":[{"given":"Ling","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angella M.","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"London M.","family":"McDougal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forrest L.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Katsanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7064-6881","authenticated-orcid":false,"given":"Richard J.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"13","key":"7888_CR1","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/bjsports-2015-094787","volume":"50","author":"JK Gerritsen","year":"2016","unstructured":"Gerritsen JK, Vincent AJ. Exercise improves quality of life in patients with cancer: a systematic review and meta-analysis of randomised controlled trials. Br J Sports Med. 2016;50(13):796\u2013803.","journal-title":"Br J Sports Med"},{"issue":"2","key":"7888_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ccell.2023.12.007","volume":"42","author":"JA Lavery","year":"2024","unstructured":"Lavery JA, Boutros PC, Knight D, Tammela T, Moskowitz CS, Jones LW. Association of exercise with pan-cancer incidence and overall survival. Cancer Cell. 2024;42(2):169\u201371.","journal-title":"Cancer Cell"},{"issue":"1","key":"7888_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa2502760","volume":"393","author":"KS Courneya","year":"2025","unstructured":"Courneya KS, Vardy JL, O\u2019Callaghan CJ, Gill S, Friedenreich CM, Wong RKS, et al. Structured exercise after adjuvant chemotherapy for colon cancer. N Engl J Med. 2025;393(1):13\u201325.","journal-title":"N Engl J Med"},{"issue":"8","key":"7888_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular Mol Immunol. 2020;17(8):807\u201321.","journal-title":"Cellular Mol Immunol"},{"key":"7888_CR5","doi-asserted-by":"crossref","unstructured":"Gustafson MP, Wheatley-Guy CM, Rosenthal AC, Gastineau DA, Katsanis E, Johnson BD, et al. Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. J Immunother Cancer. 2021;9(7):e001872\u2013e.","DOI":"10.1136\/jitc-2020-001872"},{"key":"7888_CR6","doi-asserted-by":"crossref","unstructured":"Collier-Bain HD, Brown FF, Causer AJ, Emery A, Oliver R, Moore S, et al. Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review. Front Oncol. 2023;13.","DOI":"10.3389\/fonc.2023.1244090"},{"issue":"4","key":"7888_CR7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41577-023-00943-0","volume":"24","author":"C Fiuza-Luces","year":"2024","unstructured":"Fiuza-Luces C, Valenzuela PL, G\u00e1lvez BG, Ram\u00edrez M, L\u00f3pez-Soto A, Simpson RJ, et al. The effect of physical exercise on anticancer immunity. Nat Rev Immunol. 2024;24(4):282\u201393.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"7888_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1249\/JES.0000000000000114","volume":"45","author":"RJ Simpson","year":"2017","unstructured":"Simpson RJ, Bigley AB, Agha N, Hanley PJ, Bollard CM. Mobilizing immune cells with exercise for cancer immunotherapy. Exercise Sport Sci Rev. 2017;45(3):163\u201372.","journal-title":"Exercise Sport Sci Rev"},{"key":"7888_CR9","doi-asserted-by":"crossref","unstructured":"Rayner CJ, Bartlett DB, Allen SK, Wooldridge T, Seymour T, Sunshine S, et al. Prehabilitation during neoadjuvant chemotherapy results in an enhanced immune response in esophageal adenocarcinoma tumors: a randomized controlled trial. J Sport Health Sci. 2025;101063\u2013.","DOI":"10.1016\/j.jshs.2025.101063"},{"issue":"3","key":"7888_CR10","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.cmet.2016.01.011","volume":"23","author":"L Pedersen","year":"2016","unstructured":"Pedersen L, Idorn M, Olofsson Gitte H, Lauenborg B, Nookaew I, Hansen Rasmus H, et al. Voluntary running suppresses tumor Growth through epinephrine- and IL-6-Dependent NK cell mobilization and redistribution. Cell Metab. 2016;23(3):554\u201362.","journal-title":"Cell Metab"},{"issue":"7","key":"7888_CR11","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ccell.2022.05.006","volume":"40","author":"E Kurz","year":"2022","unstructured":"Kurz E, Hirsch CA, Dalton T, Shadaloey SA, Khodadadi-Jamayran A, Miller G, et al. Exercise-induced engagement of the IL-15\/IL-15R\u03b1 axis promotes anti-tumor immunity in pancreatic cancer. Cancer Cell. 2022;40(7):720\u201337.e5.","journal-title":"Cancer Cell"},{"issue":"7","key":"7888_CR12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1158\/2326-6066.CIR-20-0499","volume":"9","author":"IL Gomes-Santos","year":"2021","unstructured":"Gomes-Santos IL, Amoozgar Z, Kumar AS, Ho WW, Roh K, Talele NP, et al. Exercise training improves tumor control by increasing CD8+ T-cell infiltration via CXCR3 signaling and sensitizes breast cancer to immune checkpoint blockade. Cancer Immunol Res. 2021;9(7):765\u201378.","journal-title":"Cancer Immunol Res"},{"key":"7888_CR13","doi-asserted-by":"crossref","unstructured":"Batatinha H, Diak DM, Niemiro GM, Baker FL, Smith KA, Z\u00fa\u00f1iga TM, et al. Human lymphocytes mobilized with exercise have an anti-tumor transcriptomic profile and exert enhanced graft-versus-leukemia effects in xenogeneic mice. Front Immunol. 2023;14.","DOI":"10.3389\/fimmu.2023.1067369"},{"key":"7888_CR14","doi-asserted-by":"crossref","unstructured":"Casciano F, Caruso L, Zauli E, Gonelli A, Zauli G, Vaccarezza M. Emerging mechanisms of physical exercise benefits in adjuvant and neoadjuvant cancer immunotherapy. Biomedicines. 2024;12(11):2528\u2013.","DOI":"10.3390\/biomedicines12112528"},{"key":"7888_CR15","doi-asserted-by":"crossref","unstructured":"Hapuarachi B, Danson S, Wadsley J, Muthana M. Exercise to transform tumours from cold to hot and improve immunotherapy responsiveness. Front Immunol. 2023;14.","DOI":"10.3389\/fimmu.2023.1335256"},{"key":"7888_CR16","doi-asserted-by":"crossref","unstructured":"Dima D, Jiang D, Singh DJ, Hasipek M, Shah HS, Ullah F, et al. Multiple myeloma therapy: emerging trends and challenges. Cancers. 2022;14(17):4082\u2013.","DOI":"10.3390\/cancers14174082"},{"key":"7888_CR17","volume-title":"Multiple myeloma: available therapies and causes of drug resistance","author":"V Pinto","year":"2020","unstructured":"Pinto V, Bergantim R, Caires HR, Seca H, Guimar\u00e3es JE, Vasconcelos MH. Multiple myeloma: available therapies and causes of drug resistance. Cancers: MDPI AG; 2020."},{"key":"7888_CR18","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9).","DOI":"10.1038\/s41408-020-00359-2"},{"issue":"8","key":"7888_CR19","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.bbmt.2019.04.005","volume":"25","author":"A D\u2019Souza","year":"2019","unstructured":"D\u2019Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, et al. A phase 2 study of Pembrolizumab during Lymphodepletion after autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2019;25(8):1492\u201397.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"7888_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/hemato2020012","volume":"2","author":"N Gagelmann","year":"2021","unstructured":"Gagelmann N, Kr\u00f6ger N. Donor lymphocyte Infusion to enhance the graft-versus-myeloma effect. Hemato. 2021;2(2):207\u201316.","journal-title":"Hemato"},{"key":"7888_CR21","doi-asserted-by":"crossref","unstructured":"Nozzoli C, Pucillo M, Giaccone L, Rambaldi A, Stanghellini MTL, Benedetti E, et al. Novel drug combinations and donor lymphocyte infusions allow prolonged disease control in multiple myeloma patients relapsing after allogeneic transplantation. Transplant Cellular Ther. 2025;31(1):.e26.1\u2013.13.","DOI":"10.1016\/j.jtct.2024.10.015"},{"key":"7888_CR22","doi-asserted-by":"crossref","unstructured":"Pu J, Liu T, Sharma A, Jiang L, Wei F, Ren X, et al. Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma. Exp Hematol Oncol. 2024;13(1):105\u2013.","DOI":"10.1186\/s40164-024-00576-6"},{"issue":"5","key":"7888_CR23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","volume":"31","author":"M Sheykhhasan","year":"2024","unstructured":"Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, Poondla N, Tanzadehpanah H, Dirbaziyan A, et al. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther. 2024;31(5):667\u201386.","journal-title":"Cancer Gene Ther"},{"key":"7888_CR24","doi-asserted-by":"crossref","unstructured":"Zhang L, Peng X, Ma T, Liu J, Yi Z, Bai J, et al. Natural killer cells affect the natural course, drug resistance, and prognosis of multiple myeloma. Front Cell Dev Biol. 2024;12.","DOI":"10.3389\/fcell.2024.1359084"},{"key":"7888_CR25","doi-asserted-by":"crossref","unstructured":"Wang W. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015;6.","DOI":"10.3389\/fimmu.2015.00368"},{"key":"7888_CR26","doi-asserted-by":"crossref","unstructured":"Collier-Bain HD, Emery A, Brown FF, Causer AJ, Oliver R, Eddy R, et al. Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro. Brain, Behav, Immun - Health. 2024;42:100865\u2013.","DOI":"10.1016\/j.bbih.2024.100865"},{"issue":"23","key":"7888_CR27","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","volume":"1","author":"T Casneuf","year":"2017","unstructured":"Casneuf T, Xu XS, Adams HC, Axel AE, Chiu C, Khan I, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017;1(23):2105\u201314.","journal-title":"Blood Adv"},{"issue":"1","key":"7888_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2217\/fon-2022-0975","volume":"19","author":"B Paul","year":"2023","unstructured":"Paul B, Liedtke M, Khouri J, Rifkin R, Gandhi MD, Kin A, et al. A phase II multi-arm study of magrolimab combinations in patients with relapsed\/refractory multiple myeloma. Future Oncol. 2023;19(1):7\u201317.","journal-title":"Future Oncol"},{"key":"7888_CR29","doi-asserted-by":"crossref","unstructured":"McDougal LM, Baker FL, Gustafson MP, Katsanis E, Simpson RJ. Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation. Front Immunol. 2025;16.","DOI":"10.3389\/fimmu.2025.1563972"},{"key":"7888_CR30","doi-asserted-by":"crossref","unstructured":"Z\u00fa\u00f1iga TM, Baker FL, Smith KA, Batatinha H, Lau B, Gustafson MP, et al. Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells. Front Immunol. 2022;13.","DOI":"10.3389\/fimmu.2022.938106"},{"issue":"2","key":"7888_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40262-016-0432-1","volume":"56","author":"N Chen","year":"2017","unstructured":"Chen N, Zhou S, Palmisano M. Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clin Pharmacokinet. 2017;56(2):139\u201352.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"7888_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/BF00614309","volume":"30","author":"D Loew","year":"1986","unstructured":"Loew D, Schuster O, Graul EH. Dose-dependent pharmacokinetics of dexamethasone. Eur J Clin Pharmacol. 1986;30(2):225\u201330.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"7888_CR33","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00262-022-03322-1","volume":"72","author":"JL Thangaraj","year":"2023","unstructured":"Thangaraj JL, Jung S-H, Vo M-C, Chu T-H, Phan M-T, Lee K-H, et al. Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model. Cancer Immunol, Immunother. 2023;72(5):1233\u201346.","journal-title":"Cancer Immunol, Immunother"},{"issue":"3","key":"7888_CR34","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"de Weers M","year":"2011","unstructured":"de Weers M, Tai Y-T, van der Veer Ms, Bakker JM, Vink T, Jacobs DCH, et al. Daratumumab, a Novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. The J Immunol. 2011;186(3):1840\u201348.","journal-title":"The J Immunol"},{"key":"7888_CR35","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.bbi.2024.03.023","volume":"118","author":"HD Collier-Bain","year":"2024","unstructured":"Collier-Bain HD, Emery A, Causer AJ, Brown FF, Oliver R, Dutton D, et al. A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo. Brain, Behav, Immun. 2024;118:468\u201379.","journal-title":"Brain, Behav, Immun"},{"key":"7888_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbi.2014.12.027","volume":"49","author":"AB Bigley","year":"2015","unstructured":"Bigley AB, Rezvani K, Pistillo M, Reed J, Agha N, Kunz H, et al. Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Part II: impact of latent cytomegalovirus infection and catecholamine sensitivity. Brain, Behav, Immun. 2015;49:59\u201365.","journal-title":"Brain, Behav, Immun"},{"issue":"24","key":"7888_CR37","doi-asserted-by":"publisher","first-page":"6465","DOI":"10.1182\/blood-2011-08-372680","volume":"118","author":"CR Carter","year":"2011","unstructured":"Carter CR, Feyler S, Smalle N, Scott GB, Parrish C, Cullen K, et al. Effect of combined dexamethasone\/lenalidomide therapy on NK cell-receptor levels in myeloma patients. Blood. 2011;118(24):6465\u201366.","journal-title":"Blood"},{"issue":"2","key":"7888_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/156800910791054239","volume":"10","author":"KG A","year":"2010","unstructured":"Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor Growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets. 2010;10(2):155\u201367.","journal-title":"Curr Cancer Drug Targets"},{"issue":"7","key":"7888_CR39","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41423-021-00686-9","volume":"18","author":"JL Thangaraj","year":"2021","unstructured":"Thangaraj JL, Ahn S-Y, Jung S-H, Vo M-C, Chu T-H, Thi Phan M-T, et al. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model. Cellular Mol Immunol. 2021;18(7):1652\u201361.","journal-title":"Cellular Mol Immunol"},{"issue":"2","key":"7888_CR40","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/cncr.10244","volume":"94","author":"AS Fairey","year":"2002","unstructured":"Fairey AS, Courneya KS, Field CJ, Mackey JR. Physical exercise and immune system function in cancer survivors. Cancer. 2002;94(2):539\u201351.","journal-title":"Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07888-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07888-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07888-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:21:31Z","timestamp":1775647291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07888-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7888"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07888-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"25 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of Arizona Institutional Review Board (IRB Parent Protocol ID: 1801161041) and was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"483"}}